Ratings for Dianthus Therapeutics (NASDAQ:DNTH) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
3
0
0
0
Last 30D
0
1
0
0
0
1M Ago
0
1
0
0
0
2M Ago
1
1
0
0
0
3M Ago
1
0
0
0
0
The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.0, a high estimate of $51.00, and a low estimate of $33.00. This current average reflects an increase of 45.13% from the previous average price target of $28.25.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Dianthus Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Laura Chico
Wedbush
Raises
Outperform
$38.00
$33.00
Steven Seedhouse
Raymond James
Raises
Outperform
$51.00
$34.00
Maury Raycroft
Jefferies
Raises
Buy
$39.00
$22.00
Laura Chico
Wedbush
Raises
Outperform
$33.00
$24.00
Alex Thompson
Stifel
Announces
Buy
$44.00
-
Key Insights:
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...Full story available on Benzinga.com
Benzinga
